What is Kawasaki disease?
Kawasaki disease is an acute inflammatory condition that primarily affects children under 5 years of age, causing widespread inflammation of blood vessels throughout the body (systemic vasculitis). Despite being considered rare globally, it represents the most common cause of acquired heart disease in children in developed countries. The condition was first described by Japanese pediatrician Tomisaku Kawasaki in 1967, and while its exact cause remains unknown, prompt recognition and treatment can prevent serious cardiac complications. Without treatment, up to 25% of children develop coronary artery abnormalities that can lead to lifelong heart problems.
Key statistics
| Annual incidence: | 8-67 per 100,000 children under 5 years (varies by ethnicity and geography) |
| Peak age: | 1-2 years old (80% occur before age 5) |
| Gender ratio: | 1.5:1 male predominance |
| Mortality rate: | Less than 0.1% with appropriate treatment |
Symptoms
Primary symptoms: Prolonged fever lasting more than 5 days, bilateral conjunctivitis without discharge, polymorphous skin rash, strawberry tongue and oral changes, extremity swelling and peeling, cervical lymphadenopathy.
The hallmark of Kawasaki disease is a high fever that persists for at least five days and is often resistant to standard fever-reducing medications. Children typically appear extremely irritable and uncomfortable. The eyes become red and bloodshot (conjunctivitis) but without the thick discharge seen in infections. A widespread, variable rash appears on the trunk and may extend to the arms and legs, often more pronounced in the diaper area in infants.
Distinctive oral changes include bright red, cracked lips, a “strawberry tongue” with prominent red bumps, and generalized redness inside the mouth and throat. The hands and feet become swollen, red, and painful, followed by characteristic peeling of the skin around the fingertips and toes during the recovery phase, typically 1-3 weeks after fever onset. Many children develop swollen lymph nodes, particularly on one side of the neck.
Additional symptoms may include joint pain and swelling, abdominal pain, diarrhea, vomiting, extreme irritability, and in some cases, aseptic meningitis causing neck stiffness and headache.
Causes and risk factors
The exact cause of Kawasaki disease remains idiopathic (unknown), though research suggests it results from an abnormal immune response to an infectious trigger in genetically susceptible individuals. Current theories propose that one or more common infectious agents may trigger the condition in children with specific genetic predispositions.
Risk factors include: Age under 5 years (especially 1-2 years), male gender, Asian ethnicity (particularly Japanese and Korean heritage), family history of Kawasaki disease, and certain seasonal patterns suggesting possible infectious triggers. Siblings of affected children have a 10-fold increased risk, and children of parents who had Kawasaki disease face a doubled risk, indicating genetic susceptibility factors.
Environmental factors may include recent respiratory or gastrointestinal infections, though no specific pathogen has been definitively identified. Some studies suggest associations with carpet cleaning, recent antibiotic use, or living near bodies of water, but these remain unproven.
Prevention
Currently, there are no established methods to prevent Kawasaki disease, as the underlying cause remains unknown and the condition is not considered directly contagious. Unlike genetic conditions, there is no role for carrier testing or genetic screening, though researchers continue investigating genetic susceptibility factors.
Parents with a family history of Kawasaki disease should be aware of the symptoms and maintain close communication with their pediatrician, especially during their child’s first five years of life. Early recognition and prompt treatment remain the most effective strategies to prevent serious complications.
Complications
The most serious complications of Kawasaki disease affect the cardiovascular system. Without treatment, 20-25% of children develop coronary artery aneurysms (abnormal bulging of the heart’s blood vessels), which can lead to blood clots, heart attacks, or sudden death even in young children.
Additional cardiac complications include myocarditis (heart muscle inflammation), pericarditis (inflammation around the heart), heart rhythm abnormalities, and valvular dysfunction. In severe cases, children may develop heart failure or require cardiac catheterization procedures.
Non-cardiac complications can include gallbladder inflammation (hydrops), joint damage, hearing loss, and in rare cases, peripheral gangrene affecting fingers or toes. Long-term cardiovascular monitoring is essential even for children who don’t develop obvious coronary artery problems during the acute phase.
Diagnosis
Kawasaki disease diagnosis relies on clinical criteria, as no specific diagnostic test exists. The classic diagnostic criteria require fever lasting 5 or more days plus at least four of five principal features: bilateral conjunctivitis, oral changes, rash, extremity changes, and cervical lymphadenopathy.
Laboratory tests typically show elevated inflammatory markers including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood cell count. Platelet counts often rise significantly during the second week of illness. Additional blood tests may reveal elevated liver enzymes, low albumin levels, and anemia.
Imaging studies focus on cardiac assessment. Echocardiography (ultrasound of the heart) is performed at diagnosis and repeated at 2 weeks and 6-8 weeks to monitor for coronary artery abnormalities. Electrocardiograms may show rhythm abnormalities or signs of heart inflammation.
Some children present with “incomplete” Kawasaki disease, having fever and fewer than four principal criteria but still requiring treatment based on laboratory findings and physician judgment.
Treatment
The standard treatment combines intravenous immunoglobulin (IVIG) and high-dose aspirin, ideally administered within 10 days of fever onset to maximize effectiveness in preventing coronary artery complications.
Acute phase treatment involves IVIG given as a single high-dose infusion over 8-12 hours, along with high-dose aspirin (80-100 mg/kg/day). This combination reduces inflammation and significantly decreases the risk of coronary artery aneurysms from 25% to less than 5%.
For children who don’t respond to initial IVIG treatment (approximately 10-20%), second-line therapies include additional IVIG doses, methylprednisolone (corticosteroids), or infliximab (anti-TNF therapy).
Convalescent phase treatment transitions to low-dose aspirin (3-5 mg/kg/day) for its anti-platelet effects, typically continued for 6-8 weeks in children without coronary abnormalities, or indefinitely in those with persistent coronary artery changes.
Prognosis
With prompt diagnosis and appropriate treatment, the vast majority of children with Kawasaki disease recover completely without long-term complications. The mortality rate is less than 0.1% in developed countries with access to proper medical care.
Children treated within the first 10 days of illness have less than a 5% chance of developing coronary artery abnormalities. Even when coronary changes occur, many resolve over time, particularly smaller aneurysms. However, children with persistent large aneurysms require lifelong cardiac monitoring and may need blood-thinning medications or interventional procedures.
Long-term studies suggest that most children with uncomplicated Kawasaki disease can participate in normal activities and sports without restrictions. Those with coronary artery involvement may have activity limitations depending on the severity of their condition.
Quality of life
Most children who recover from Kawasaki disease can lead completely normal lives. During the acute illness, children are often extremely irritable and uncomfortable, requiring supportive care including adequate hydration, fever management, and comfort measures.
Recovery typically occurs gradually over several weeks, with energy levels and appetite slowly returning to normal. Parents should watch for signs of cardiac complications such as chest pain, shortness of breath, or exercise intolerance, though these are uncommon with proper treatment.
For children with ongoing coronary artery issues, lifestyle modifications may include dietary counseling to promote heart health, regular exercise within physician-recommended guidelines, and stress management. Mental health support may benefit families dealing with the anxiety of long-term cardiac monitoring.
Regular follow-up care helps ensure optimal outcomes and provides reassurance to families navigating this challenging diagnosis.
Pregnancy and fertility
Kawasaki disease does not typically affect fertility in either men or women who had the condition as children. Women with a history of Kawasaki disease can generally have normal pregnancies, though those with residual coronary artery abnormalities should receive specialized cardiac care during pregnancy.
Pregnancy management depends on the degree of coronary involvement. Women with normal coronary arteries require no special precautions, while those with aneurysms may need anticoagulation management and cardiac monitoring throughout pregnancy and delivery.
Genetic counseling may be considered for families with multiple affected members, as children of Kawasaki disease survivors have approximately twice the baseline risk of developing the condition.
Children
Since Kawasaki disease primarily affects young children, pediatric considerations are central to all aspects of care. The condition can be particularly challenging to diagnose in infants under 6 months, who may present with incomplete criteria and are at higher risk for coronary complications.
School-age children who develop Kawasaki disease may experience prolonged absences during acute illness and recovery. Educational support and communication with schools help ensure smooth transitions back to normal activities.
Parents often struggle with the diagnostic uncertainty and need for invasive procedures like IV placement and echocardiograms. Child life specialists and family support services play crucial roles in helping families cope with hospitalization and follow-up care requirements.
When to see a doctor
Seek immediate medical attention for: Any child with fever lasting more than 5 days, especially when accompanied by red eyes, rash, or oral changes. The combination of prolonged fever with any of the classic Kawasaki disease features warrants urgent pediatric evaluation.
Emergency care is needed for: Chest pain, difficulty breathing, severe abdominal pain, signs of dehydration, or extreme lethargy in any child with suspected or confirmed Kawasaki disease.
Parents should trust their instincts when their child appears unusually ill, particularly with persistent high fever that doesn’t respond to standard medications. Early recognition and treatment significantly improve outcomes.
Regional context
Limited data exists regarding Kawasaki disease incidence in the Caucasus region (Georgia, Armenia, Azerbaijan) and broader Eastern Mediterranean area. The condition appears less common in Middle Eastern and Caucasian populations compared to East Asian countries, though underdiagnosis may contribute to lower reported rates.
Healthcare providers in these regions should maintain awareness of Kawasaki disease, particularly given increasing global travel and mixed populations. The Georgian Medical Journal welcomes regional case reports and epidemiological studies to better understand local disease patterns and outcomes.
Research and clinical trials
Current research focuses on identifying the underlying cause of Kawasaki disease, improving treatment protocols for resistant cases, and developing better predictive tools for coronary artery complications. Genetic studies are investigating susceptibility factors across different populations.
Recent clinical trials have examined alternative treatments including anakinra (IL-1 receptor antagonist) and cyclosporine for IVIG-resistant patients. Research into biomarkers that could predict treatment response and coronary artery risk continues.
Families interested in research participation can search ClinicalTrials.gov for ongoing studies. International registries collect data to improve understanding of long-term outcomes and optimal management strategies.
Frequently asked questions
Is Kawasaki disease contagious?
No, Kawasaki disease is not directly contagious between children. While an infectious trigger is suspected, the disease itself doesn’t spread from person to person like typical infections.
Will my child need lifelong heart monitoring?
Most children with normal coronary arteries after acute treatment require only routine pediatric care. Those with coronary abnormalities need ongoing cardiac follow-up, with frequency depending on the severity of changes.
Can Kawasaki disease happen twice?
Recurrence is rare, occurring in less than 3% of cases. However, parents should remain vigilant for symptoms, especially during the first few years after initial diagnosis.
Are there long-term effects even without coronary problems?
Most children with uncomplicated Kawasaki disease have no long-term health effects. Some studies suggest possible subtle cardiovascular changes, but these don’t typically affect daily life or activities.
Should siblings be tested or monitored differently?
Siblings have a higher risk but don’t require special testing. Parents should be aware of symptoms and seek prompt medical care for any prolonged fever or concerning symptoms in siblings.
Support and resources
- Kawasaki Disease Foundation: www.kdfoundation.org – Comprehensive patient and family resources
- American Heart Association: www.heart.org – Cardiovascular health information
- National Organization for Rare Disorders (NORD): rarediseases.org
- Orphanet: orpha.net – Rare disease information portal
- World Health Organization: who.int – Global health resources
Related conditions
- Toxic shock syndrome
- Scarlet fever
- Juvenile idiopathic arthritis
- Stevens-Johnson syndrome
- Polyarteritis nodosa
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Kawasaki disease.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/kawasaki-disease/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?